Fig. 2: The frequency of 33 significant mutated genes (>1%) in MDS patients according to the WHO 2022 classification. | Leukemia

Fig. 2: The frequency of 33 significant mutated genes (>1%) in MDS patients according to the WHO 2022 classification.

From: Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms

Fig. 2

WHO World Health Organization, MDS myelodysplastic syndromes(neoplasms), 5q- isolated 5q deletion, biTP53 biallelic TP53 inactivation, LB low blasts, MDS-SF3B1 MDS with low blasts and SF3B1 mutation, MDS-h MDS hypoplastic, IB1/2 increased blasts type1/2, MDS-f MDS with fibrosis.

Back to article page